FDA Panel Votes 12-0 Against Effectiveness of NeurogesX's (NGSX) Qutenza
Tweet
Share
E-mailGet Alerts NGSX Hot Sheet
Join SI Premium – FREE
An FDA panel has voted 12-0 against the effectiveness of NeurogesX's (Nasdaq: NGSX) Qutenza.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
